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A B S T R A C T
Purpose
Bevacizumab (BEV) is approved in more than 60 countries for use in adults with recurrent glio-
blastoma. We evaluated the addition of BEV to radiotherapy plus temozolomide (RT+TMZ) in pe-
diatric patients with newly diagnosed high-grade glioma (HGG).
Methods
The randomized, parallel group, multicenter, open-label HERBY trial (ClinicalTrials.gov identiﬁer:
NCT01390948) enrolled patients age $ 3 years to # 18 years with localized, centrally
neuropathology-conﬁrmed, nonbrainstemHGG. Eligible patients were randomly assigned to receive
RT + TMZ (RT: 1.8 Gy, 5 days per week, and TMZ: 75mg/m2 per day for 6 weeks; 4-week treatment
break; then up to 123 28-day cycles of TMZ [cycle 1: 150mg/m2 per day, days 1 to 5; cycles 2 to 12:
200 mg/m2 per day, days 1 to 5]) with or without BEV (10 mg/kg every 2 weeks). The primary end
point was event-free survival (EFS) as assessed by a central radiology review committee that was
blinded to treatment. We report ﬁndings of EFS at 12 months after the enrollment of the last patient.
Results
One hundred twenty-one patients were enrolled (RT+TMZ [n = 59]; BEV plus RT+TMZ [n = 62]).
Central radiology review committee–assessed median EFS did not differ signiﬁcantly between
treatment groups (RT+TMZ, 11.8 months; 95% CI, 7.9 to 16.4 months; BEV plus RT+TMZ,
8.2 months; 95% CI, 7.8 to 12.7 months; hazard ratio, 1.44; P = .13 [stratiﬁed log-rank test]). In the
overall survival analysis, the addition of BEV did not reduce the risk of death (hazard ratio, 1.23; 95%
CI, 0.72 to 2.09). More patients in the BEV plus RT+TMZ group versus the RT+TMZ group ex-
perienced one ormore serious adverse events (n = 35 [58%] v n = 27 [48%]), andmore patients who
received BEV discontinued study treatment as a result of adverse events (n = 13 [22%] v n = 3 [5%]).
Conclusion
Adding BEV to RT+TMZ did not improve EFS in pediatric patients with newly diagnosed HGG. Our
ﬁndings were not comparable to those of previous adult trials, which highlights the importance of
performing pediatric-speciﬁc studies.
J Clin Oncol 36. © 2018 by American Society of Clinical Oncology
INTRODUCTION
High-grade gliomas (HGGs) are the most common
group of pediatric malignant CNS neoplasms, with
an annual incidence of 0.87 per 100,000 children in
the United States.1 Despite surgical resection fol-
lowed by radiotherapy (RT) and concomitant ad-
juvant chemotherapy, the prognosis for children
with HGG remains poor. Unlike most other cancer
types, 5-year survival is lower in pediatric patients
versus adult patients with HGG.1,2
There are substantial differences between
pediatric and adult HGG.3-5 Midline tumor lo-
cation is more frequent in children than in
adults.6,7 Whereas contrast enhancement is the
hallmark of malignant gliomas in adults, not
all pediatric HGGs exhibit contrast uptake.8,9
Platelet-derived growth factor receptor-a am-
pliﬁcation is the most common DNA copy
number change in pediatric HGG, whereas
epidermal growth factor receptor ampliﬁcation
is more commonly detected in adults.5 O6-
methylguanine DNA methyltransferase (MGMT)
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promoter expression is also less frequent in pediatric patients
compared with adult patients with HGG.10 A key difference in
pediatric HGGs compared with adult HGGs is the presence of unique
somatic H3F3A (histone H3.3) driver mutations at position K27M
and G34R/Vof the regulatory tail,11 which suggests that results from
adult trials may not be directly transferable to pediatric patients with
the same histologically deﬁned disease.
Bevacizumab (BEV) is approved in more than 60 countries
worldwide for use in adults with recurrent glioblastoma.12,13
Clinical experience with BEV in pediatric patients with HGG is
limited, although the addition of BEV to irinotecan in 31 children
with recurrent malignant glioma or intrinsic brainstem glioma
demonstrated some efﬁcacy and was well tolerated.14 The HERBY
trial aimed to evaluate the efﬁcacy and safety of adding BEV to
postoperative radiotherapy plus temozolomide (RT+TMZ) in
pediatric patients with newly diagnosed, localized HGG.
METHODS
Study Design
A Study of Bevacizumab (Avastin) in Combination with Temozo-
lomide (TMZ) and Radiotherapy in Paediatric and Adolescent Participants
With High-Grade Giloma (HERBY) was a phase II, open-label, ran-
domized, international, comparator study of the addition of BEV to RT
+TMZ in pediatric patients (age $ 3 to# 18 years) with newly diagnosed
HGG. Here, we present event-free survival (EFS) data at 12 months after
enrollment of the last patient.
HERBY was conducted as part of a pediatric investigation plan and in
accordance with applicable country regulations, International Council for
Harmonisation of Technical Requirements for Pharmaceuticals for Human
Use Good Clinical Practice Guidelines, and the Declaration of Helsinki.
Written informed consent was obtained from the patient, parents, or
legally acceptable representatives before enrollment and the collection of
tissue for exploratory biomarker analyses.
Eligible patients were centrally randomly assigned 1:1 on the basis of
a minimization algorithm via an interactive voice response system to
receive BEV plus RT+TMZ or RT+TMZ with the following stratiﬁcation
factors: age ($ 3 to# 5 years,$ 6 to# 12 years, and$ 13 to# 18 years),
WHO grade (III v IV), and type of surgery (total/near total resection v
others; Fig 1). Random assignment was performed via minimization with
biased coin assignment.15 Patients and investigators were not masked to
treatment assignment; the central radiology review committee (CRRC) was
masked to group allocation.
Study treatment started at least 28 days after cranial surgery and no
later than 6 weeks after the last major surgery. Patients received RT (1.8 Gy
per session for 30 sessions, 5 days per week, for a total of 54 Gy) and TMZ
75 mg/m2 per day for 6 weeks, followed by a minimum 4-week TMZ
treatment break, then up to 123 28-day cycles of TMZ (cycle 1: 150 mg/m2
per day, days 1 to 5; cycles 2 to 12: 200 mg/m2 per day, days 1 to 5). Patients
who were assigned to BEV treatment additionally received BEV 10 mg/kg
every 2 weeks, whichwas delivered concomitantly with RT+TMZ (concurrent
phase), alone during the TMZ treatment break, and subsequently with up to
123 28-day cycles of TMZ (adjuvant phase). Concomitant corticosteroid use
and stable doses of anticoagulants were permitted.
Patients
Patients aged $ 3 to # 18 years with newly diagnosed, localized,
supratentorial or infratentorial cerebellar or peduncular, grade III and IV
gliomas (according to WHO 2007 guidelines) were enrolled. Local his-
tologic diagnosis was conﬁrmed by a central reference neuropathologist
before enrollment. The availability of a baseline magnetic resonance imaging
scan and the ability to commence trial treatment 4 to 6 weeks after surgery
were also required. Key exclusion criteria includedmetastatic HGG deﬁned as
evidence of neuro-axis dissemination by magnetic resonance imaging or
positive CSF cytology; gliomatosis cerebri (extensive glioma, ie, involving at
least three cerebral lobes according to WHO 2007 guidelines), multifocal
glioma, diffuse intrinsic pontine glioma, or intramedullary HGG; pleo-
morphic xanthoastrocytoma or anaplastic ganglioglioma; prior diagnosis of
a malignancy, including low-grade glioma, and not disease free for 5 years;
prior systemic anticancer therapy; previous cranial irradiation; any signiﬁcant
cardiovascular disease or unresolved infection; or chronic daily treatment with
aspirin (. 325 mg per day) or clopidogrel (. 75 mg per day).
Study Assessments
Patients were observed for a minimum of 1 year after random as-
signment. Tumor progression and/or recurrence and BEV response were
determined by using Response Assessment in Neuro-Oncology criteria in
HGG.16 Tumor evaluations were performed at baseline, at the end of the
TMZ break, every 3 months during the adjuvant phase and the ﬁrst 3 years
post–random assignment, and every 6 months thereafter until progression
and/or recurrence.17
Random
assignment
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every two weeks
Debulking
surgery
or biopsy
Treatment start
4-6 weeks postsurgery
Concurrent phase
6 weeks
TMZ treatment 
break 4 weeks
Maintenance phase
up to 12 cycles 
BEV
10 mg/kg
every 2 weeks
Treatment break
Central
pathology
review
Fig 1. Study design. BEV, bevacizumab; HGG, high-grade glioma; RT, radiotherapy; TMZ, temozolomide.
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Health-related quality of life was assessed in patients$ 5 years of age
by using the Health Utility Index (HUI) questionnaire,18 which was
completed at screening, at cycle 6 of the adjuvant phase, at the end of
treatment, yearly during the follow-up period, at the time of progression,
and at the end-of-study visit. Neuropsychological assessment using the
Wechsler scale adapted for age was measured at the end of treatment, every
2 years during the follow-up period, and at the end-of-study visit.
Study End Points
EFS was the prespeciﬁed primary end point, which was deﬁned as the
earliest occurrence of tumor progression and tumor recurrence (CRRC
assessed), second primary non-HGG malignancy, or death attributable to
any cause. Prespeciﬁed secondary end points included overall survival (OS)
and 1-year OS rate, 6-month and 1-year EFS rates (CRRC assessed),
objective response rate (ORR; CRRC assessed using Response Assessment
in Neuro-Oncology criteria), investigator-assessed EFS, health status as
measured by HUI (patients age$ 5 years), neuropsychological function as
measured by the Wechsler scale adapted for age, and safety. We performed
post hoc exploratory analyses of EFS (CRRC assessed) and OS by histone
mutation status and tumor location.
Safety
Adverse events (AEs) and serious AEs (SAEs) were reported from
study treatment initiation to 28 days after the last dose of the study treatment.
AEs of special interest (AESIs), regardless of the relationship to the study
treatment, were reported up to 6 months after the last dose of the study
treatment. After 6 months, only study treatment–related SAEs were reported.
Statistical Analysis
Analysis populations included the intent-to-treat population (all
randomly assigned patients regardless of whether they received study
treatment), the efﬁcacy-evaluable population (all randomly assigned pa-
tients with at least one post–random assignment assessment from the local
investigator), and the safety-evaluable population (all randomly assigned
patients who received at least one dose of the study treatment). Baseline
characteristics were compared between treatment groups by using x2,
Mann-Whitney-Wilcoxon, or Kruskal-Wallis tests as appropriate.
The primary end point of CRRC-assessed EFS was estimated by using
Kaplan-Meiermethodology and compared between treatment groups by using
a stratiﬁed log-rank test (two-sided) at a 5% level of signiﬁcance. Stratiﬁcation
factors were age, HGG WHO grade, and the extent of surgery. Estimates of
treatment effect (BEV plus RT+TMZ vRT+TMZ) stratiﬁed for covariates were
expressed as hazard ratios (HRs) with 95% CIs estimated in a Cox pro-
portional hazards regression model. Investigator-assessed EFS and OS were
analyzed by using a two-sided log-rank test. Safety data are described according
to the maximum grade of intensity reported per preferred term, per patient.
Additional details on the study assessments, AESI deﬁnitions, and
statistical analyses performed, including sample size calculations, interim
futility analysis, and prespeciﬁed sensitivity analyses are available in the
Appendix (online only).
RESULTS
Patients
Between October 2011 and February 2015, 174 patients were
screened (53 patients were excluded at screening), and 121were randomly
assigned to receive treatment (RT+TMZ [n = 59]; BEV plus RT+TMZ
[n= 62]; Fig 2).Overall, 116 patients (RT+TMZ [n = 56]; BEV plus
RT+TMZ[n=60]) received the study treatment at 51 sites in 14 countries.
Baseline characteristics were balanced, with no signiﬁcant
differences between treatment groups for any of the variables listed
in Table 1. MGMT promotor status was assessed in 42 patients, of
whom 37 had an unmethylated tumor (RT+TMZ [n = 18]; BEV
plus RT+TMZ [n = 19]; Table 1). H3F3A mutation status was
assessed in 85 patients, of whom 31 showed evidence of a mutation
(RT+TMZ [n = 15]; BEV plus RT+TMZ [n = 16]; Table 1). Mu-
tations were observed at position K27M in 24 patients (RT+TMZ
[n = 10]; BEV plus RT+TMZ [n = 14]) and at position G34R/V in
seven patients (RT+TMZ [n = 5]; BEV plus RT+TMZ [n = 2];
Table 1). Additional MGMT promotor and histone mutation status
ﬁndings from subsequent analyses using non-prespeciﬁed tests are
reported in a separate paper (Mackay A, et al. [In submission]).
The median duration of survival follow-up was similar between
treatment groups (RT+TMZ: 15.2months; range, 0.1 to 46.8months;
and BEV plus RT+TMZ: 16.2 months; range, 0 to 45.7 months).
Interim Analysis
The study was considered futile after the prespeciﬁed interim
analysis, which was performed after the ﬁrst 60 randomly assigned
patients were observed for 1 year; however, as patient recruitment
had been completed, and there were no safety concerns by the time
the interim analysis was performed, the independent data mon-
itoring committee recommended continuing the treatment of
ongoing patients per the protocol.
Primary Efficacy End Point
Median CRRC-assessed EFS for RT+TMZ and BEV plus
RT+TMZ was 11.8 months (95% CI, 7.9 to 16.4 months) and
8.2months (95%CI, 7.8 to 12.7months), respectively (stratiﬁedHR,
1.44; 95%CI, 0.90 to 2.30;P= .13; Fig 3). The earliest contributing event
was tumor progression (RT+TMZ [n = 35]; BEV plus RT+TMZ
[n = 38]), death (each group [n = 3]), tumor recurrence (RT+TMZ
[n = 1]; BEV plus RT+TMZ [n = 4]), and second primary non-HGG
malignancy (osteosarcoma [RT+TMZ] and B-cell acute lymphocytic
leukemia [BEV plus RT+TMZ]; each group [n = 1]). Results were
generally consistent across the different subgroups (Fig 4), although
females who received RT+TMZ demonstrated a better outcome than did
those who received BEVplus RT+TMZ (HR, 2.10; 95%CI, 1.04 to 4.21).
Secondary Efficacy End Points
The 1-year CRRC-assessed EFS rates were 48% (95% CI, 35%
to 61%) and 38% (95% CI, 26% to 51%) for RT+TMZ and BEV
plus RT+TMZ, respectively. The 1-year OS rates were 68% (95%CI,
54% to 78%) and 75% (95% CI, 61% to 84%), respectively. As
a result of the absence of measurable lesions at baseline, only 27
patients were eligible for CRRC-assessedORR analysis. Among these
patients, ORR was 40% (six of 15 patients) and 42% (ﬁve of 12
patients) in the RT+TMZ and BEV plus RT+TMZ groups, re-
spectively. Results for investigator-assessed EFS (HR, 1.49; 95% CI,
0.92 to 2.40) were similar to those for CRRC-assessed EFS. The
addition of BEV did not reduce the risk of death (HR, 1.23; 95% CI,
0.72 to 2.09; Fig 5). OS data are immature; a ﬁnal OS analysis will be
performed once 5 years of follow-up are available. The most common
pattern of progression in both groups was local recurrence (RT+TMZ
[n = 25]; BEV plus RT+TMZ [n = 23]).More patients in the BEV plus
RT+TMZ group (n = 15) than in the RT+TMZ group (n = 8)
demonstrated both local and distant recurrence.
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Treatment Received
During the concurrent phase, 95% and 98% of patients
treated with RT+TMZ and BEV plus RT+TMZ, respectively,
completed $ 90% of planned RT doses, and 86% and 88% of
patients, respectively, completed $ 90% of planned TMZ doses.
Correspondingly, during the adjuvant phase, 45% and 33% of
patients, respectively, completed 12 TMZ cycles. The total and per-
cycle TMZ dose received was comparable between groups for the
concurrent and adjuvant phases. Patients in the BEV plus RT
+TMZ group received a median of 5.0 and 18.5 BEV adminis-
trations during the concurrent and adjuvant phases, respectively.
Safety
Themedian duration of safety follow-up was 11.7 months and
11.6 months in the RT+TMZ and BEV plus RT+TMZ groups,
respectively. No new safety signals were identiﬁed for BEV. All
patients, with the exception of one in the BEV plus RT+TMZ
group, experienced at least one AE. The incidence of grade 3 to 5
AEs was similar across the groups (RT+TMZ [n = 38; 68%] v BEV
plus RT+TMZ [n = 42; 70%]), but more patients experienced
a grade 3 to 5 AESI in the BEV plus RT+TMZ group (n = 13; 22%)
than in the RT+TMZ group (n = 3; 5%). The most common AESIs
were proteinuria (RT+TMZ [n = 0; 0%] v BEV plus RT+TMZ
[n = 8; 13%]) and arterial thromboembolic events (RT+TMZ [n = 2;
4%] v BEV plus RT+TMZ [n = 5; 8%]). More patients experienced
at least one SAE in the BEV plus RT+TMZ group (n = 35; 58%)
than in the RT+TMZ group (n = 27; 48%), and a higher
proportion of patients discontinued any component of study
treatment as a result of AEs in the BEV plus RT+TMZ group (n = 13;
22%) than in the RT+TMZ group (n = 3; 5%). More patients in the
BEV plus RT+TMZ group (n = 43; 72%) experienced AEs that led to
dose modiﬁcations of any component of study treatment than in the
RT+TMZ group (n = 34; 61%).
In the BEV plus RT+TMZ group, BEV and TMZ were dis-
continued as a result of AEs in 20% and 5% of patients, re-
spectively. Among patients who discontinued BEV because of an
AE, the most common reason was proteinuria (n = 6; 10%). At the
clinical cutoff date, four of the proteinuria events had resolved after
BEV discontinuation, and two were ongoing.
Deaths occurred in 28 patients (50%) in the RT+TMZ group
and 33 patients (55%) in the BEV plus RT+TMZ group. The cause of
death in all but one patient was disease progression. One treatment-
related grade 4 AE of atypical teratoid/rhabdoid tumor of the CNS
occurred in the BEV plus RT+TMZ group 2 years after the end of the
study treatment and resulted in death. Additional details on patient
disposition and protocol deviations in this study, and results of the
interim futility analysis, sensitivity analyses, health-related quality of
life and neuropsychological function assessments, and exploratory
analyses of potential prognostic factors are available in the Appendix.
DISCUSSION
The HERBY study evaluated the efﬁcacy and safety of BEV plus
RT+TMZ versus RT+TMZ alone in pediatric patients with newly
Screened
(N = 174)
Enrolled
(n = 121)
Randomly assigned
(RT+TMZ; n = 59)
Randomly assigned
(BEV plus RT+TMZ; n = 62)
Treated
(n = 56)
Treated
(n = 60)
Ongoing
treatment
(n = 0)
Completed
treatment
(n = 25)
Discontinued
treatment
(n = 31)
Ongoing
treatment
(n = 0)
Discontinued
treatment
(n = 43)
Completed
treatment
(n = 17)
Withdrew from
follow-up
(n = 2)
Alive at
follow-up or
survival follow-up
(n = 26)
Died
(n = 28)
Withdrew from
follow-up
(n = 4)
Alive at
follow-up or
survival follow-up
(n = 23)
Died
(n = 33)
Survival follow-up
(n = 6)
Survival follow-up
(n = 6)
Fig 2. CONSORT ﬂow diagram. Survival
follow-up was an unlimited follow-up that
continued to capture patient survival after
regular follow-up had been completed. Five
randomly assigned patients did not receive
treatment (radiotherapy plus temozolomide
[RT+TMZ]: withdrew consent [n = 3]; bev-
acizumab [BEV] plus RT+TMZ: failed to meet
eligibility criteria [n = 1]; withdrew consent
[n = 1]).
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diagnosed nonbrainstem HGG. On the basis of a prespeciﬁed
interim analysis of the ﬁrst 60 randomly assigned patients who
were observed for 1 year, the study was considered futile; however,
as patient recruitment had been completed and there were no
safety concerns, the independent data monitoring committee
recommended the continued treatment of patients per the
protocol. This work presents the updated analysis of the enrolled
121 patients in the main protocol who were observed for at least 1
year after random assignment, unless patient withdrawal or death
occurred.
Table 1. Patient Baseline Characteristics of the Intent-to-Treat Population (all randomly assigned patients regardless of whether they received the study treatment)
Characteristic
RT+TMZ
(n = 59)
BEV Plus RT+TMZ
(n = 62)
Total
(n = 121)
Median age (range), years 11.0 (3-17) 10.0 (3-17) 11.0 (3-17)
Age group, No. (%), years*
3 to # 5 6 (10) 10 (16) 16 (13)
6 to # 12 30 (51) 35 (57) 65 (54)
13 to # 18 23 (39) 17 (27) 40 (33)
Male, No. (%) 36 (61) 34 (55) 70 (58)
WHO grade HGG, No. (%)*
III 17 (29) 20 (32) 37 (31)
IV 42 (71) 42 (68) 84 (69)
Surgery, No. (%)*
Total/near total resection 29 (49) 31 (50) 60 (50)
Other resection 20 (34) 19 (31) 39 (32)
Biopsy 10 (17) 12 (19) 22 (18)
MGMT gene promotor status, No. (%)
Methylated 2 (3) 3 (5) 5 (4)
Unmethylated with ratio , 0.6 18 (31) 19 (31) 37 (31)
Missing 39 (66) 40 (65) 79 (65)
Histone mutation status, No. (%)
No mutation 29 (49) 25 (40) 54 (45)
Mutation at position G34 5 (9) 2 (3) 7 (6)
Mutation at position K27 10 (17) 14 (23) 24 (20)
Missing 15 (25) 21 (34) 36 (30)
Location of HGG, No. (%)
Midline 18 (31) 24 (39) 42 (35)
Other 41 (69) 38 (61) 79 (65)
Residual tumor at baseline, No. (%)†
Contrast-enhancing lesions 15 (25) 12 (19) 27 (22)
Non–contrast-enhancing lesions 47 (80) 49 (79) 96 (79)
Abbreviations: BEV, bevacizumab; HGG, high-grade glioma; MGMT, O6-methyguanine-DNA methyltransferase; RT, radiotherapy; TMZ, temozolomide.
*Stratiﬁcation factors for random assignment.
†Patients could have both enhancing and nonenhancing lesions.
Stratified HR, 1.44
95% CI, 0.90 to 2.30; log-rank P = .13
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Fig 3. Central radiology review committee–
assessed event-free survival with radiotherapy
plus temozolomide (RT+TMZ) and bevacizumab
(BEV) plus RT+TMZ (primary efﬁcacy end point).
HR, hazard ratio.
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There was no signiﬁcant difference in CRRC-assessed EFS—the
primary end point—between treatment groups, and the results of
the secondary end points, including investigator-assessed EFS, ORR,
and OS, demonstrated no improvement with the addition of BEV.
No new safety signals were identiﬁed for BEV; however, a higher
proportion of patients in the BEV plus RT+TMZ group than in the
RT+TMZ group discontinued study treatment as a result of toxicity.
Patients in the RT+TMZ group had a higher-than-expected 1-year
EFS rate of 48% (95% CI, 35% to 61%), which is comparable to
a previously reported 1-year EFS rate of 38% with RT+TMZ2 and
49% with TMZ plus lomustine.19
The absence of an EFS beneﬁt with BEV in our study is not
consistent with results from adult trials in which BEV has been
shown to delay radiologic progression, although neither adult
study demonstrated an OS beneﬁt.20,21 Biologic differences between
pediatric and adult HGGs may explain, in part, why children re-
spond differently to treatments.3,4 Most patients in our study had
non–contrast-enhancing lesions at baseline (79%), whereas adult
HGGs are typically contrast enhancing.8 In addition, the proportion
of patients in our study with MGMT unmethylated tumors was
lower than that reported in adult patients with HGG,10 which
suggests a phenotypic difference. This highlights the importance of
conducting pediatric-speciﬁc HGG trials to assess the beneﬁt of
potential treatments.
Between-group differences in tumor location may also have
contributed to the lower-than-anticipated efﬁcacy observed with
BEV—39% of patients in the BEV plus RT+TMZ group had midline
tumors versus 31% in the RT+TMZ group. Indeed, a previous study
Baseline Risk Factors
All patients
Sex
Male
Female
Age group, years
3 to ≤ 5
6 to ≤ 12
13 to < 18
Bone age group, years
Unknown
3 to ≤ 5
6 to ≤ 12
13 to < 18
≥ 18
HGG WHO grade
III
IV
Surgery
Total/near total resection
Other
Race
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Nonwhite
White
121
70
51
16
65
40
7
16
56
35
7
37
84
60
61
4
17
100
BEV Plus  RT+TMZ Better RT+TMZ Better
Location of HGG
Midline
Other
MGMT gene promoter status
Methylated
Unmethylated with ratio < 0.6
Missing data
Histone mutation status
No mutation
Mutation at position G34
Mutation at position K27
Missing data
Karnofsky performance status
10-50
60-70
80-100
Lansky play-performance status
60-70
80-100
42
79
5
37
79
54
7
24
36
1
7
36
9
62
11/100 100
No. of Patients
Hazard Ratio
(Wald 95% CI)
1.18 (0.77 to 1.81)
0.83 (0.48 to 1.46)
2.10 (1.04 to 4.21)
1.26 (0.31 to 5.06)
0.94 (0.53 to 1.66)
1.88 (0.88 to 4.02)
1.23 (0.19 to 8.10)
0.60 (0.17 to 2.09)
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demonstrated poorer outcomes in patients with midline tumors
versus other locations, although the study did not describe how
midline was deﬁned.22 In the current study, midline location was
associated with poorer EFS than were tumors in other locations
(Appendix). In addition, the effect of some biologic prognostic
factors that were not anticipated at the time of the study design may
have affected survival. Histone H3 K27M mutations, which are
observed in midline tumors, have been associated with a poor
prognosis, whereas mutations at G34R/V, observed in hemispheric
tumors, may be associated with slightly longer OS.23 In our study,
H3F3A driver mutations at position K27M and G34M were asso-
ciated with lower survival (Appendix). Some differences in the
proportion of patients with these mutations were evident between
groups; however, this ﬁnding should be interpreted with caution as
multiple statistical tests were performed in a relatively small number
of samples. MGMT methylation status has also been shown to
inﬂuence response to TMZ24; however, MGMT methylation was
relatively balanced between groups for the relatively small number of
patients who were assessed for MGMT methylation status in this
study.
Themost common pattern of progressive disease in both groups
was local recurrence, although a greater proportion of patients who
received BEV demonstrated both local and distant progression.
Previous research has suggested that BEV may lead to a higher in-
cidence of distant and diffuse disease in pediatric patients with HGG
or diffuse intrinsic pontine glioma,25 and adult studies have noted
a greater proportion of distant lesions in patients who received BEV,26
although other studies reported no change in the radiographic
pattern of patients’ tumors between baseline and the time of disease
progression in patients who received BEV.27
Limitations of this study include the heterogeneity of enrolled
patients, the relatively short follow-up duration, and the low
completion rate of the HUI questionnaire at follow-up. The sta-
tistical power of the study was limited by the relatively small
number of enrolled patients; however, increasing the study sample
size would be unlikely to change the point estimate for survival, but
may reduce the associated CI. Despite this, the HERBY trial is
one of the largest prospective, randomized pediatric HGG trials to
date, including a molecular evaluation of tumor characteristics and
providing a global picture of treatment efﬁcacy. We have dem-
onstrated the feasibility of real-time, central histopathologic review
before study entry, with no delay in treatment initiation. Only 5%
of patients were excluded for having noneligible low-grade glioma
compared with up to 30% in a trial that used post hoc central
review.27 The availability of results within 4 years of the adult trial
demonstrates successful pharma–academic cooperation.
In conclusion, adding BEV to RT+TMZ did not improve EFS
in pediatric patients with newly diagnosed HGG. These results are
not fully consistent with adult studies and highlight the biologic
differences between adult and childhood HGG, as well as the
importance of performing pediatric-speciﬁc studies.
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Appendix
METHODS
Study Assessments
The central radiology review committee (CRRC) performed a prospective review in patients with investigator-determined
radiologic progression at ﬁrst or second magnetic resonance imaging scan to ensure that discontinuation was not prematurely
decided as a result of pseudoprogression, deﬁned as a non–tumor-related increase in contrast enhancement observed on magnetic
resonance imaging scan, typically occurring within the ﬁrst 12 weeks after concomitant radiotherapy plus temozolomide
(RT+TMZ), that then stabilizes or decreases over time in the absence of treatment modiﬁcation. If subsequent imaging showed
progression, the time of progression was backdated. A central efﬁcacy read was performed by two independent radiologists in
parallel and adjudicated when needed. In addition, the adjudicated radiology data were reviewed alongside clinical data by an
independent oncologist. Objective response rate—a complete or partial response (. 50%) on two consecutive occasions$ 4 weeks
apart—was evaluated in patients with measurable disease at baseline and based on the blinded evaluation by the CRRC using
Response Assessment in Neuro-Oncology criteria.16
DNA for the assessment of O6-methylguanine-DNA methyltransferase (MGMT; by OncoMethylome’s MGMT assay) and
histone status were extracted from sections of formalin-ﬁxed parafﬁn-embedded tissue blocks that were collected at the time of
central pathology review.
Safety
Adverse events (AEs) were graded according to the National Cancer Institute Common Toxicity Criteria for Adverse Events
(version 4.0). AEs of special interest were based on grouping AE terms by speciﬁc Medical Dictionary for Regulatory Activities
baskets and standard Medical Dictionary for Regulatory Activities queries and included hypertension grade $ 3; proteinuria
grade $ 3; GI perforation, abscesses, or ﬁstula (any grade); wound-healing complications grade $ 3; hemorrhage grade $ 3 (any
grade CNS bleeding; grade 2 hemoptysis); arterial thromboembolic events (any grade); venous thromboembolic events grade$ 3;
posterior reversible encephalopathy syndrome or reversible posterior leukoencephalopathy syndrome (any grade); congestive heart
failure grade $ 3; and non-GI ﬁstula or abscess grade $ 2.
Statistical Analysis
The sample size of this study was based on pragmatic considerations. A total enrollment of 120 patients was considered
achievable over 3 years of accrual. Assuming an exponential model with a hazard ratio of 0.65 between the treatment
groups—1-year event-free survival (EFS) of 30% in the RT+TMZ group and 46% in the bevacizumab (BEV) plus RT+TMZ
group—the power of the log-rank test—two-sided, with an a of 5%—for a sample size of 60 patients per group was 60%.
A prespeciﬁed interim futility analysis was performed on the basis of the ﬁrst 60 randomly assigned patients who were observed
for 1 year. If a protocol-speciﬁed threshold of a 10% greater improvement in the 1-year EFS rate in the BEV plus RT+TMZ group
versus the RT+TMZ group was not met, the study would be considered futile.
Prespeciﬁed sensitivity analyses included an unstratiﬁed analysis of CRRC-assessed EFS, and an unstratiﬁed analysis of CRRC-
assessed EFSwith censoring of the data for patients who discontinued the study for any reason before experiencing an EFS event.We
conducted exploratory multivariable Cox proportional hazards regression analyses to assess the impact of prognostic factors on EFS
(age, bone age at baseline, high-grade glioma grade, complete resection or biopsy,MGMT gene promotor status, histone mutation
status, Karnofsky performance status, and Lansky play-performance status). As an additional exploratory, post hoc sensitivity
analysis, we assessed the heterogeneity of the effect of BEV according to stratiﬁcation variables and other potential baseline
prognostic factors in multivariable models, including interaction terms, shown in a forest plot.
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RESULTS
Patients
One hundred seventy-four patients were screened for enrollment, and 53 patients were excluded with screening. The most
common reasons for screening failure included the failure to meet criteria, which included conﬁrmation of local histologic
diagnosis by a designated central reference neuropathologist (n = 17) and newly diagnosed localized, supratentorial or infratentorial
cerebellar or peduncular, WHO grade III or IV gliomas (n = 9) after central radiologic review. Of patients, 5% had noneligible low-
grade glioma and were excluded.
Patient Disposition and Protocol Deviations
Patients received study treatment at 51 sites in 14 countries—Australia, Austria, Belgium, Canada, Czech Republic, Denmark,
France, Hungary, Italy, the Netherlands, Poland, Spain, Sweden, and the United Kingdom.
There were 14 major protocol deviations (RT+TMZ [n = 8]; BEV plus RT+TMZ [n = 6]), including continued study treatment
after experiencing progressive disease or an AE that warranted treatment discontinuation (RT+TMZ [n = 8]; BEV plus RT+TMZ
[n = 5]). One patient in the BEV plus RT+TMZ group underwent surgery before progressive disease. There was no crossover
between treatment groups.
Sensitivity Analyses of the Primary Efficacy End Point
Results of sensitivity analyses performed on CRRC-assessed EFS were consistent with the primary analysis (Appendix Table A1,
online only).
Health-Related Quality of Life
Mean baseline absolute scores for the Health Utility Index (HUI) questionnaire were balanced between the treatment groups
(0.97 with RT+TMZ [n = 40] and 0.96 with BEV plus RT+TMZ [n = 46]). At cycle 6 (day 1), mean changes from baseline in HUI
score were 20.004 and 0.034 for the RT+TMZ (n = 24) and BEV plus RT+TMZ (n = 35) groups, respectively (a change in mean
overall HUI score of 0.03 is considered a clinically meaningful difference; Horsman et al: Health Qual Life Outcomes. 1: 54, 2003);
however, only four patients in the RT+TMZ group and three patients in the BEV plus RT+TMZ group completed the questionnaire
at follow-up.
Neuropsychological Function
Neuropsychological function assessments were available for more than one half of patients during the treatment period, but
availability decreased signiﬁcantly for the follow-up period as a result of death and the withdrawal of consent. At end-of-treatment
follow-up visit 1, assessments from 47 patients were available. Overall, patients for whom data were collected had normal cognitive
function, an absence of motor deﬁcit dysfunction, no seizures, an absence of raised intracranial pressure, and normal speech and
language.
Prognostic Factors
Age, high-grade glioma grade (according to the WHO 2007 guidelines), and MGMT promoter status were not associated with
an effect on EFS. Midline tumor location, biopsy only, and histone H3 K27M mutation were associated with lower EFS (Appendix
Fig A1, online only). Multivariable Cox proportional hazards regression analysis revealed no signiﬁcant association between
potential baseline prognostic factors and EFS, but midline tumor location (v other) and a histone mutation at position G34 (v no
mutation) were associated with poorer overall survival (Appendix Table A2, online only).
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Fig A1. (A) Impact of tumor location, (B) extent of resection, and (C) histone mutation status on CRRC-assessed
event-free survival. CI, conﬁdence interval; CRRC, Central Radiology Review Committee; HR, hazard ratio. *A
signiﬁcance threshold of 0.01 was used for these analyses.
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Table A2. Multivariable Cox Proportional Hazards Regression Analysis of the
Impact of Prognostic Factors on CRRC-Assessed EFS and OS
Variable Effect Size HR SE P
CRRC-assessed EFS
Treatment
BEV plus RT+TMZ 0.047 1.048 0.287 .8690
Age group, years
3 to # 5 20.091 0.913 0.517 .8603
6 to # 12 0.331 1.393 0.299 .2675
WHO-deﬁned grade of HGG
IV 0.332 1.393 0.315 .2928
Resection
Other 0.075 1.078 0.298 .8010
Female sex 20.215 0.806 0.264 .4151
Tumor location
Midline 0.595 1.812 0.485 .2205
Histone status
Mutation at position G34 0.724 2.062 0.444 .1027
Mutation at position K27 0.318 1.375 0.510 .5325
OS
Treatment
BEV plus RT+TMZ 20.133 0.876 0.332 .6900
Age group, years
3 to , 6 20.269 0.764 0.606 .6571
6 to , 13 0.618 1.856 0.365 .0899
WHO-deﬁned grade of HGG
IV 0.204 1.226 0.360 .5719
Resection
Other 0.228 1.256 0.339 .5002
Female sex 20.170 0.844 0.306 .5792
Tumor location
Midline 1.274 3.576 0.545 .0193
Histone status
Mutation at position G34 1.167 3.212 0.498 .0191
Mutation at position K27 0.067 1.069 0.547 .9033
NOTE. Covariates included treatment (v RT+TMZ), age group (v 13 to , 18
years), WHO-deﬁned grade of HGG (v III), resection complete or biopsy (v total
or near total resection), sex (vmale), tumor location (v other), and histone status
(v no mutation).
Abbreviations: BEV, bevacizumab; CRRC, central radiology review committee;
EFS, event-free survival; HGG, high-grade glioma; HR, hazard ratio; OS, overall
survival; RT, radiotherapy; SE, standard error; TMZ, temozolomide.
Table A1. Summary of Sensitivity Analyses on Central Radiology Review
Committee–Assessed Event-Free Survival
Sensitivity Analysis
RT+TMZ
(n = 59)
BEV Plus RT+TMZ
(n = 62)
Unstratiﬁed analysis
Median, months 11.8 8.2
HR (95% CI) 1.18 (0.77 to 1.81)
Censoring for new anticancer therapy
Median, months 11.8 8.2
HR (95% CI) 1.44 (0.90 to 2.30)
Censoring for treatment discontinuation
Median, months 16.4 14.5
HR (95% CI) 1.41 (0.80 to 2.49)
Abbreviations: BEV, bevacizumab; HR, hazard ratio; RT, radiotherapy; TMZ,
temozolomide.
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